PKPDExposure-response

Dazukibart IFN-beta and dermatomyositis response

A PK/PD exposure-response model linking intravenous dazukibart disposition and IFN-beta binding to delayed changes in cutaneous, muscle, functional, and global disease assessments.

Explore and simulate

Therapeutic: Dazukibart
Target: IFNB1, interferon-beta
Disease: Dermatomyositis

Biological model

A PK/PD exposure-response model linking intravenous dazukibart disposition and IFN-beta binding to delayed changes in cutaneous, muscle, functional, and global disease assessments.

Intervention

Dazukibart

Biological focus

IFNB1, interferon-beta

Context

Dermatomyositis

Model details

A PK/PD exposure-response model linking intravenous dazukibart disposition and IFN-beta binding to delayed changes in cutaneous, muscle, functional, and global disease assessments.

Modeled states

central mgmg

Modeled dynamic state for central mg.
depot mgmg

Modeled dynamic state for depot mg.
end cdasi adimensionless

Modeled dynamic state for end cdasi a.
end cdasi ddimensionless

Modeled dynamic state for end cdasi d.
end enzymedimensionless

Modeled dynamic state for end enzyme.
end exgadimensionless

Modeled dynamic state for end exga.
end haqdimensionless

Modeled dynamic state for end haq.
end mmt8dimensionless

Modeled dynamic state for end mmt8.
end phgadimensionless

Modeled dynamic state for end phga.
end ptgadimensionless

Modeled dynamic state for end ptga.
end sf36 mcsdimensionless

Modeled dynamic state for end sf36 mcs.
end sf36 pfddimensionless

Modeled dynamic state for end sf36 pfd.

Key readouts

Dazukibart concentrationunknown

Model-derived readout for dazukibart concentration.
Free IFN-betaunknown

Model-derived readout for free ifn-beta.
CDASI activity responsedimensionless

Model-derived readout for cdasi activity response.
MMT-8 responsedimensionless

Model-derived readout for mmt-8 response.
Physician global responsedimensionless

Model-derived readout for physician global response.

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Starting configuration

Stage 1 600 mg IV every 4 weeks x3

How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures? Explore this intervention regimen through Dazukibart concentration, Free IFN-beta, CDASI activity response, MMT-8 response, Physician global response. This is a mechanistic product exploration, not a paper-result reproduction.

Questions to explore

How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures?

Starting result

This result reflects the starting settings. Run your changes to update it.

This scenario result is temporarily unavailable.

Model inputs

Five scientist-facing controls at most.

cl l week Model parameter controlling cl l week. L/weekvc l Model parameter controlling vc l. Lka week Model parameter controlling ka week. 1/weekkss pm Model parameter controlling kss pm. pMkout week Model parameter controlling kout week. 1/week

Compare a parameter

How does one model input change the response?

How does dazukibart exposure alter free IFN-beta and the time course of dermatomyositis response measures?

Parameter to compare

cl l week

Model parameter controlling cl l week.

Exploratory range around the default value.

Low High Points

5 evenly spaced values in L/week. Other model inputs and the simulation window stay fixed.

Interpret with care

Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.

Review the server-confirmed fixed price before starting the comparison.

Comparative response

End-of-window response across the selected parameter values.

Choose an exploratory range around the default, review the fixed price, and run the comparison.

Scientific reference

Supporting publication

Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis

Journal of Pharmacokinetics and Pharmacodynamics